Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 8c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.84), $0.08 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $59 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
• Concrete Pumping Holdings (BBCP) Tops Q3 EPS by 1c
• UBS Reiterates Buy Rating on Linde (LIN) as Challenges in Helium Are 'Being Managed'